We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
(+5.9%)
Cap. Flow
-$43.5M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$41.2M |
| 2 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$21.9M |
| 3 |
United Therapeutics
UTHR
|
+$14.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$12.5M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$21.8M |
| 2 |
Steris
STE
|
+$20M |
| 3 |
Illumina
ILMN
|
+$18.6M |
| 4 |
Waters Corp
WAT
|
+$17.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.67% |
| 2 | Real Estate | 2.94% |
| 3 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$383B
| $126M | 4.11% |
315,548
+103,263
| +49% | +$41.2M |
|
2
Amgen
AMGN
$209B
| $113M | 3.67% |
463,405
+46,845
| +11% | +$11.5M |
|
3
Gilead Sciences
GILD
$163B
| $113M | 3.66% |
1,634,785
-181,121
| -10% | -$12.1M |
|
4
Moderna
MRNA
$23B
| $109M | 3.56% |
465,777
-6,525
| -1% | -$1.17M |
|
|
5
Illumina
ILMN
$31B
| $95.5M | 3.1% |
207,460
-46,243
| -18% | -$18.6M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $87.7M | 2.85% |
936,340
+125,408
| +15% | +$11.5M |
|
7
Abbott
ABT
$183B
| $87.1M | 2.83% |
750,997
+7,340
| +1% | +$856K |
|
8
Johnson & Johnson
JNJ
$617B
| $85.1M | 2.77% |
516,652
-88,212
| -15% | -$14.6M |
|
9
Vertex Pharmaceuticals
VRTX
$122B
| $79.7M | 2.59% |
395,288
| – | – |
|
10
Regeneron Pharmaceuticals
REGN
$77.4B
| $77.2M | 2.51% |
138,132
-15,373
| -10% | -$7.79M |
|
11
Biogen
BIIB
$30.7B
| $72.4M | 2.35% |
209,124
-37,720
| -15% | -$11.4M |
|
|
12
Thermo Fisher Scientific
TMO
$214B
| $70.7M | 2.3% |
140,130
+26,477
| +23% | +$12.5M |
|
13
AbbVie
ABBV
$455B
| $69.5M | 2.26% |
617,303
-2,456
| -0.4% | -$277K |
|
14
Medtronic
MDT
$110B
| $67.9M | 2.21% |
546,722
+54,508
| +11% | +$6.84M |
|
15
Eli Lilly
LLY
$1.03T
| $58.9M | 1.91% |
256,561
-35,553
| -12% | -$7.14M |
|
16
Cigna
CI
$76.1B
| $50M | 1.63% |
211,018
+21,097
| +11% | +$5.27M |
|
17
Danaher
DHR
$138B
| $44.6M | 1.45% |
187,519
-28,200
| -13% | -$6.25M |
|
|
18
Bristol-Myers Squibb
BMY
$132B
| $43.8M | 1.42% |
655,973
-236,480
| -26% | -$15.4M |
|
19
Merck
MRK
$321B
| $42.1M | 1.37% |
541,703
-26,002
| -5% | -$1.93M |
|
|
20
Elevance Health
ELV
$81.6B
| $41.1M | 1.34% |
107,734
-57,043
| -35% | -$21.8M |
|
21
Stryker
SYK
$133B
| $39.1M | 1.27% |
150,500
-1,330
| -0.9% | -$340K |
|
22
Zimmer Biomet
ZBH
$18.4B
| $35.8M | 1.16% |
229,384
+15,336
| +7% | +$2.48M |
|
23
DexCom
DXCM
$28.8B
| $35.3M | 1.15% |
331,020
+32,448
| +11% | +$3.12M |
|
24
ResMed
RMD
$30.3B
| $34M | 1.1% |
137,807
+5,463
| +4% | +$1.15M |
|
|
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
| $33.3M | 1.08% |
210,759
-14,731
| -7% | -$2.19M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.
- Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
- Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
- Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
- Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
- Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
- Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
- Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.
Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.